Press release from Companies
Publicerat: 2022-11-14 08:30:00
(Stockholm, 14 November 2022) In September 2022 Inhalation Sciences Sweden AB (ISAB) was awarded an FDA BAA (Broad Agency Announcement) contract for a research project evaluating the discriminative power of its DissolvIt® in vitro dissolution technology. The project has now had its Kick-off meeting and is underway. ISAB has communicated previously on this project, most recently on 15 September 2022.
The objective of contract 75F40122C00197 is to evaluate the discriminative power of ISAB’s DissolvIt® technology by comparing drug formulations, aimed for administration via inhalation, with small differences. The project scope also includes in vitro in vivo correlation (IVIVC). The proposed work was approved by the FDA Center for Drug Evaluation and Research (CDER). ISAB’s CEO Manoush Masarrat: "We are pleased to have begun work on this project. It is a valuable opportunity for us to further explore the potential of the DissolvIt® method in evaluating the dissolution of inhalable substances in the lung." For more information on Inhalation Sciences, please contact: Manoush Masarrat, CEO E-mail: Manoush.masarrat@inhalation.se Mobile: +46 (0)73 628 9153 About Inhalations Sciences Sweden AB (publ) Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments and services for research into inhalation. The company’s patented lab instruments PreciseInhale® and DissolvIt® enable researchers in the pharma industry to make drug pipeline decisions at an early stage, saving time and resources for R&D departments, and enables researchers in academic institutions to define how aerosols and small particles impact our lungs, whether new pollutants or life-saving drugs that power human development.
